Inventor · disambiguated record
Bohan Jin
Also filed as: JIN BOHAN
18 granted patents·10 pending applications·52 citations·filing 2009–2025
91Inventor score
Files withALUMIS INC6JIN BOHAN4TAKEDA PHARMACEUTICAL4FRONTHERA U S PHARMACEUTICALS LLC3MOLECULAR AXIOM LLC3
Top patents by PatentIndex Score
28 records- 0196US11053219B2Substituted pyridines as TYK2 inhibitorsFRONTHERA U S PHARMACEUTICALS LLC·Filed 2020·Granted Jul 6, 2021·9 cites·57 claims
- 0292US11964964B2Thyroid hormone receptor agonists and uses thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2019·Granted Apr 23, 2024·8 cites·18 claims
- 0392US11731956B2Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitorsALUMIS INC·Filed 2022·Granted Aug 22, 2023·1 cites·2 claims
- 0490US11040972B2Autotaxin inhibitors and uses thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2020·Granted Jun 22, 2021·2 cites·21 claims
- 0587US12006306B2Substituted pyridazines as TYK2 inhibitorsALUMIS INC·Filed 2021·Granted Jun 11, 2024·1 cites·16 claims
- 0686US8268819B2Hexahydrooxazinopterine compoundsJIN BOHAN·Filed 2012·Granted Sep 18, 2012·11 cites·8 claims
- 0785US12351572B2Substituted 1,2,4-triazoles as TYK2 inhibitorsALUMIS INC·Filed 2023·Granted Jul 8, 2025·0 cites·7 claims
- 0885US8791107B2N-substituted oxazinopteridines and oxazinopteridinonesCHANG EDCON·Filed 2012·Granted Jul 29, 2014·10 cites·13 claims
- 0984US8163755B2Hexahydrooxazinopterine compoundsJIN BOHAN·Filed 2010·Granted Apr 24, 2012·9 cites·17 claims
- 1079US12060343B2Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitorsALUMIS INC·Filed 2022·Granted Aug 13, 2024·0 cites·6 claims
- 1176US10711000B2Autotaxin inhibitors and uses thereofFRONTHERA U S PHARMACEUTICALS LLC·Filed 2019·Granted Jul 14, 2020·1 cites·20 claims
- 1274US12358899B2Thyroid hormone receptor agonists and uses thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2024·Granted Jul 15, 2025·0 cites·13 claims
- 1365US2025276977A1Tyk2 inhibitors and uses thereofALUMIS INC·Filed 2025·Application pending·0 cites
- 1459US2024392293A1Compositions and methods for modulating kras expressionMOLECULAR AXIOM LLC·Filed 2022·Application pending·0 cites
- 1559US2022177486A1Tyk2 inhibitors and uses thereofESKER THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1657US2024182894A1Compositions and methods for modulating sos gene expressionsMOLECULAR AXIOM LLC·Filed 2022·Application pending·0 cites
- 1756US2024409931A1Compositions and methods for modulating nlrp3 or nlrp1 expressionMOLECULAR AXIOM LLC·Filed 2022·Application pending·0 cites
- 1855US2023357273A1Tyk2 inhibitors and uses thereofALUMIS INC·Filed 2021·Application pending·0 cites
- 1954US9643966B2Compounds for the treatment of cancer and inflammatory diseasesJIN BOHAN·Filed 2014·Granted May 9, 2017·0 cites·18 claims
- 2053US9045496B2N-substituted oxazinopteridines and oxazinopteridinonesTAKEDA PHARMACEUTICAL·Filed 2014·Granted Jun 2, 2015·0 cites·8 claims
- 2152US2022017566A1Terpinoid derivatives and uses thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 2251US2009246198A1Mapk/erk kinase inhibitors and methods of use thereofTAKEDA PHARMACEUTICAL·Filed 2009·Application pending·0 cites
- 2351US2011178070A1PI3K/mTOR INHIBITORSTAKEDA PHARMACEUTICAL·Filed 2009·Application pending·0 cites
- 2445US9440977B2Compositions, uses and methods for their preparationJIN BOHAN·Filed 2014·Granted Sep 13, 2016·0 cites·7 claims
- 2544US11034671B2Apoptosis signal-regulating kinase inhibitors and uses thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2018·Granted Jun 15, 2021·0 cites·16 claims
- 2641US10787430B2Hemoglobin modifier compounds and uses thereofFRONTHERA U S PHARMACEUTICALS LLC·Filed 2017·Granted Sep 29, 2020·0 cites·18 claims
- 2741US9956208B2Compounds for the treatment of cancer and inflammatory diseasesC2 PHARMACEUTICALS LLC·Filed 2017·Granted May 1, 2018·0 cites·17 claims
- 2834US2011021515A1Dihyrofuropyrmindine compoundsTAKEDA PHARMACEUTICAL·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bohan Jin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →